AAE: Alpha Amylase Enzyme; ALP: Alkaline phosphatase ; ALT: Alanine aminotransferase; ANC: Absolute Neutrophil Count; ANA: antinuclear antibodies; Anti-dsDNA, anti-double-stranded DNA antibody; AST: Aspartate aminotransferase ; AZA: azathioprine; BMI: Body mass index; BP : blood pressure; BUN: blood urea nitrogen; CAO: Conscious, Alert, and Oriented; CT: computed tomography ; Cre: creatinine; CTX, cefotaxime;  ; CRP, C-reactive protein ;EAT: Empirical antibiotic therapy ; FDP: Fibrinogen-degradation product; GGT: gamma-glutamyl transferase; Hb: Hemoglobin; HCQ: hydroxychloroquine; Hct: hematocrit; HR: heart rate; hsTnT: high‐sensitivity troponin T; mRNA: messenger ribonucleic acid; MP: methylprednisolone; NBM: Nil By Mouth ; T-bill: total bilirubin ; TG: triglyceride; PT: Prothrombin time; RIF: right iliac fossa; RR: Respiratory rate; SpO2: oxygen saturation, SLE: systemic lupus erythematosus; USG: ultrasound sonography test ; WBC: white blood cell count.

The 17 included studies described a total of 17 patients with: age groups, gender distribution and time to onset of symptoms described separately for each disease. history/comorbidities, test COVID-19, type of COVID-19 vaccine, dose, symptoms, and treatment were evenly distributed. Most cases were associated with Pfizer-BioNTech vaccine (mRNA) with 64.71 %, followed by Modern (mRNA) (11.76 %), BBIBP-CorV (Sinopharm) (11.76 %) and Johnson & Johnson / Jassen vaccine (Viral Vector) (11.76 %), most cases associated with the first dose (52.94 %). Among the symptoms, acute abdominal pain was present in almost all studies (82.35 %), other studies reported Epigastric pain (17.64 %). No death was reported in any study, all patients recovered, and most were discharged in the following weeks. Treatment was medical in most cases (88.34 %) and only one (11.76 %) required surgical treatment. The clinical and demographic characteristics are shown in detail inTable 2 .

Table 2. Clinical and demographic characteristics of the included studies (n=17).